{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:39:36Z","timestamp":1713919176466},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"DOI":"10.7759\/cureus.58805","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T10:01:10Z","timestamp":1713866470000},"source":"Crossref","is-referenced-by-count":0,"title":["Stepwise Incremental Dose Schedule of Sirolimus Is Successfully Tolerated by a Patient With Lymphangioleiomyomatosis Who Was Initially Allergic to mTOR Inhibitors"],"prefix":"10.7759","author":[{"given":"Kuniaki","family":"Seyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko K","family":"Okura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Sekimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Mitsuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"Goncharova EA","year":"2002","unstructured":"Goncharova EA, Goncharov DA, Eszterhas A, et al.. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002, 277:30958-30967. 10.1074\/jbc.M202678200","journal-title":"J Biol Chem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack FX","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, et al.. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011, 364:1595-1606. 10.1056\/NEJMoa1100391","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2277","article-title":"Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis","volume":"133","author":"Harari S","year":"2008","unstructured":"Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest. 2008, 133:448-454. 10.1378\/chest.07-2277","journal-title":"Chest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.06.016","article-title":"The NHLBI Lam registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis","volume":"155","author":"Gupta N","year":"2019","unstructured":"Gupta N, Lee HS, Ryu JH, et al.. The NHLBI Lam registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis. Chest. 2019, 155:288-296. 10.1016\/j.chest.2018.06.016","journal-title":"Chest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu GY","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020, 21:183-203. 10.1038\/s41580-019-0199-y","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201605-335OC","article-title":"Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis","volume":"13","author":"Takada T","year":"2016","unstructured":"Takada T, Mikami A, Kitamura N, et al.. Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis. Ann Am Thorac Soc. 2016, 13:1912-1922. 10.1513\/AnnalsATS.201605-335OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014535200","article-title":"Rapid oral desensitization to everolimus","volume":"48","author":"Karlin E","year":"2014","unstructured":"Karlin E, Allinder JM, Dworski R, Stollings JL. Rapid oral desensitization to everolimus. Ann Pharmacother. 2014, 48:1095-1096. 10.1177\/1060028014535200","journal-title":"Ann Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.11.007","article-title":"Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis","volume":"4","author":"Sebaaly J","year":"2016","unstructured":"Sebaaly J, Bowers L, Mazur J, Kotloff R, Olmsted BR, Kaplan A, Strange C. Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. J Allergy Clin Immunol Pract. 2016, 4:352-353. 10.1016\/j.jaip.2015.11.007","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000325340","article-title":"Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis","volume":"53","author":"Mitani K","year":"2009","unstructured":"Mitani K, Kumasaka T, Takemura H, et al.. Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol. 2009, 53:402-409. 10.1159\/000325340","journal-title":"Acta Cytol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201709-1965ST","article-title":"Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society\/Japanese Respiratory Society clinical practice guideline","volume":"196","author":"Gupta N","year":"2017","unstructured":"Gupta N, Finlay GA, Kotloff RM, et al.. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society\/Japanese Respiratory Society clinical practice guideline. Am J Respir Crit Care Med. 2017, 196:1337-1348. 10.1164\/rccm.201709-1965ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST- 3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French JA","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, et al.. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST- 3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016, 388:2153-2163. 10.1016\/S0140-6736(16)31419-2","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2013.03.002","article-title":"Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis","volume":"51","author":"Ando K","year":"2013","unstructured":"Ando K, Kurihara M, Kataoka H, et al.. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig. 2013, 51:175-183. 10.1016\/j.resinv.2013.03.002","journal-title":"Respir Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter J","year":"2015","unstructured":"Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015, 14:1055-1070. 10.1517\/14740338.2015.1040388","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17099","article-title":"Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3","volume":"62","author":"Franz DN","year":"2021","unstructured":"Franz DN, Lawson JA, Yapici Z, et al.. Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. Epilepsia. 2021, 62:3029-3041. 10.1111\/epi.17099","journal-title":"Epilepsia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald JB","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015, 72:221-238. 10.1016\/j.jaad.2014.07.033","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102373","article-title":"The immunobiology of mTOR in autoimmunity","volume":"110","author":"Suto T","year":"2020","unstructured":"Suto T, Karonitsch T. The immunobiology of mTOR in autoimmunity. J Autoimmun. 2020, 110:102373. 10.1016\/j.jaut.2019.102373","journal-title":"J Autoimmun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241912-stepwise-incremental-dose-schedule-of-sirolimus-is-successfully-tolerated-by-a-patient-with-lymphangioleiomyomatosis-who-was-initially-allergic-to-mtor-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T10:01:14Z","timestamp":1713866474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241912-stepwise-incremental-dose-schedule-of-sirolimus-is-successfully-tolerated-by-a-patient-with-lymphangioleiomyomatosis-who-was-initially-allergic-to-mtor-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.58805","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}